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Background: The extracellular matrix (ECM) has a key role in facilitating the progression of ovarian cancer and we
have shown recently that the secreted ECM protein TGFBI modulates the response of ovarian cancer to
paclitaxel-induced cell death.
Results: We have determined TGFBI signaling from the extracellular environment is preferential for the cell surface
αvβ3 integrin heterodimer, in contrast to periostin, a TGFBI paralogue, which signals primarily via a β1
integrin-mediated pathway. We demonstrate that suppression of β1 integrin expression, in β3 integrin-expressing
ovarian cancer cells, increases adhesion to rTGFBI. In addition, Syndecan-1 and −4 expression is dispensable for
adhesion to rTGFBI and loss of Syndecan-1 cooperates with the loss of β1 integrin to further enhance adhesion to
rTGFBI. The RGD motif present in the carboxy-terminus of TGFBI is necessary, but not sufficient, for SKOV3 cell
adhesion and is dispensable for adhesion of ovarian cancer cells lacking β3 integrin expression. In contrast to TGFBI,
the carboxy-terminus of periostin, lacking a RGD motif, is unable to support adhesion of ovarian cancer cells.
Suppression of β3 integrin in SKOV3 cells increases resistance to paclitaxel-induced cell death while suppression of
β1 integrin has no effect. Furthermore, suppression of TGFBI expression stimulates a paclitaxel resistant phenotype
while suppression of fibronectin expression, which primarily signals through a β1 integrin-mediated pathway,
increases paclitaxel sensitivity.
Conclusions: Therefore, different ECM components use distinct signaling mechanisms in ovarian cancer cells and in
particular, TGFBI preferentially interacts through a β3 integrin receptor mediated mechanism to regulate the
response of cells to paclitaxel-induced cell death.
Keywords: Chemotherapy, Cell adhesion, Ovarian cancer, Integrin receptor, Extracellular matrixBackground
Ovarian cancer is the deadliest gynaecological cancer in
women with the development of chemotherapeutic drug
resistance being the major obstacle to successful treat-
ment. Recent data suggests that the extracellular matrix
(ECM) can directly modulate cell sensitivity to both plat-
inum- and taxane-based drug treatment therapies [1-4].
Also, as the ECM regulates other key aspects of cell be-
haviour including growth control, cell migration, sur-
vival, and gene expression [5], it represents an important
target in designing treatment therapies.* Correspondence: james.brenton@cancer.org.uk
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distribution, and reproduction in any mediumWe have shown that the secreted extracellular matrix
protein, TGFBI (transforming growth factor beta induced),
is a critical component of the ovarian cancer tumor micro-
environment that sensitizes cells to paclitaxel-induced cell
death by stabilizing microtubules via integrin-mediated ac-
tivation of focal adhesion kinase (FAK) and the Rho family
GTPase RhoA [1]. TGFBI has been suggested to have both
tumor suppressor and tumor promoting properties, de-
pending on the cancer of origin [6]. Specifically, TGFBI
has been shown to be underexpressed in breast [7], ovar-
ian, and lung cancer [8]; and overexpressed in clear cell
renal carcinoma [9], pancreatic cancer [10], and colorectal
cancer [11]. In addition, mice lacking Tgfbi show spontan-
eous tumor formation, further supporting a potential
tumor suppressor function [12]. Interestingly, loss oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion and chromosomal instability, both causal factors asso-
ciated with carcinogenesis and drug resistant phenotypes
[1,12,13]. However, the mechanism by which extracellular
TGFBI mediates these effects is unclear.
Structurally, TGFBI contains an amino-terminal signal
peptide sequence necessary for secretion into the extra-
cellular environment, a cysteine-rich EMI domain similar
to regions found in proteins of the EMILIN family, along
with four highly conserved fasciclin I (FAS I) domains
and a carboxy-terminal Arginine-Glycine-Aspartic Acid
(RGD) motif. Various heterodimeric integrin receptor
combinations mediate interactions with TGFBI and its
RGD and FAS I domains [14-16]. Specifically, corneal
epithelial cell adhesion to TGFBI is predominantly
mediated by the α3β1 integrin heterodimer [14], while in
endothelial cells the αvβ3 integrin heterodimer is domin-
ant [15]. Furthermore, TGFBI can bind many ECM pro-
teins including Collagen type I, II, IV, and VI [17-19],
fibronectin [20], periostin [21], laminin [18], as well as
the proteoglycans biglycan and decorin [22]. The FAS
domains are highly conserved and three human proteins,
TGFBI, periostin, and stabilin, contain these motifs [23].
Periostin is a paralogue of TGFBI and is also a TGFβ1-
inducible secreted protein. Both TGFBI and periostin
have been implicated in ovarian cancer [1,24]. Periostin
is secreted by ovarian cancer, similar to TGFBI, and pro-
motes integrin-mediated cell motility [24]. However, al-
though they have similar domain structure, very little is
known as to whether their function is complementary or
antagonistic. Periostin shares with TGFBI an EMI do-
main and four highly conserved FAS I domains. How-
ever, it differs in having an extended carboxy-terminus,
which does not contain the RGD motif [25,26]. Interest-
ingly, recent data suggests periostin and TGFBI interact
through their amino-terminal EMI domains and may
have a proactive role in the pathogenesis of corneal dys-
trophy [21]. Additionally, periostin contributes to metas-
tasis in both pancreatic and colon cancer due to
augmentation of PI3K/Akt signaling [27,28] and it has
been suggested to be a critical component of metastatic
colonization [29]. Therefore, evaluating the mechanism
of TGFBI and periostin function in ovarian cancer cells
may shed light on their relationship and function during
ovarian carcinogenesis.
Although TGFBI has been shown to signal through
multiple integrin heterodimeric receptors, the predomin-
ant signaling pathways and the relationship to other
ECM components in ovarian cancer is unknown. It has
been shown that fibronectin-integrin signaling could
protect breast cancer cells against paclitaxel-induced cell
death [30]. Since this contrasts to the function of TGFBI
in ovarian cancer [1], there lacks a clear understanding
of the differential signaling that occurs upon engagementof the cell surface with various ECM components. Im-
portantly, previous reports have suggested that cross-talk
between different integrin receptors can modulate the
response to their respective ECM ligand [31-33].
To understand the function of TGFBI in ovarian can-
cer and the role of TGFBI-integrin interactions in medi-
ating paclitaxel sensitivity, we therefore delineated the
primary domains of TGFBI that are important in mediat-
ing the interaction with ovarian cancer cells and the key
receptors necessary for this process.
Methods
Antibodies and reagents
Paclitaxel was purchased from Sigma-Aldrich, cat. no.
T7402 (Dorset, UK). The GRGDSP peptide was pur-
chased from Merck Chemicals Ltd. (Nottinghamshire,
UK) and the ERGDEL peptide was custom produced by
Sigma Genosys (Haverhill, UK). Human plasma fibronec-
tin was purchased from Millipore (Watford, UK) and
human vitronectin was purchased from R&D systems
Europe Ltd. (Abingdon, UK). Affinity purified polyclonal
antibody directed against TGFBI was produced by im-
munizing rabbits with a C-terminal peptide of human
TGFBI (aa 498–683). All antibody production was per-
formed in collaboration with Cambridge Research Bio-
chemicals (Cleveland, UK). TGFBI polyclonal antiserum
was a kind gift from Dr. Ching Yuan (University of Min-
nesota, Minnesota, USA). Alpha-tubulin antibody was
purchased from Sigma-Aldrich. The periostin polyclonal
antibody was purchased from BioVendor Laboratory
Medicine Inc. (Czech Republic) and the periostin mono-
clonal antibody (clone 345613) from R&D Systems
Europe Ltd. Akt phospho-S473 and pan-Akt polyclonal
antibodies were purchased from Cell Signaling. Fibronec-
tin, ILK, and FAK phospho-Y397 monoclonal antibodies
were purchased from BD Biosciences (Oxford Science
Park, Oxford, UK). Alexa Fluor 568-phalloidin was pur-
chased from Invitrogen (Inchinnan Business Park, Pais-
ley, UK). β3 integrin polyclonal antibody was purchased
from Santa Cruz (Santa Cruz, California) and β1 integrin
polyclonal antibody was purchased from Cambridge Bio-
science (Cambridge, UK). Integrin blocking antibodies
against β1 integrin (clone P5D2), αvβ3 (clone LM609),
and αvβ5 (clone P1F6) were purchased from Millipore.
Syndecan-1 monoclonal antibody was purchased from
Serotec (Oxford, UK) and Syndecan-4 polyclonal anti-
body was purchased from R&D Systems Europe Ltd.
Cell culture
The ovarian cancer SKOV3 cell line was maintained
in RPMI media supplemented with 10% (v/v) heat-
inactivated FBS, 50 units/ml penicillin, and 50 μg/ml
streptomycin. The ovarian cancer PEO1 cell line was
maintained in DMEM/F12 (50:50) supplemented with
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and 50 μg/ml streptomycin. NIH 3 T3 cells were main-
tained in DMEM supplemented with 10% (v/v) heat
inactivated FBS, 50 units/ml penicillin, and 50 μg/ml
streptomycin. All cell lines were verified by short tandem
repeat genotyping. Lentivirus expressing individual
shRNA targeted against β1 integrin, β3 integrin, TGFBI,
and fibronectin were purchased from Sigma-Aldrich
MissionW shRNA library. Cells were infected at an MOI
of 10 and subsequently stable pools of cells were selected
in Puromycin. Syndecan-1 siGenome SMARTpoolW
siRNA, syndecan-4 siGenome SMARTpoolW, β1 integrin
ON-TARGETplusW pool, β3 integrin ON-TARGETplusW
pool, and siGenomeW non-target control #2 siRNA were
purchased from Perbio (Northumberland, UK). siRNA
transfections were performed using Lipofectamine 2000
(Invitrogen, Inchinnan Business Park, Paisley, UK)
according to manufacturer’s instructions.
Western blot
Cell lysates were harvested in RIPA buffer (1% Triton X-
100, 0.1% SDS, 1% DOC, 10 mM Tris–HCl pH 7.4,
150 mM NaCl, 5 mM EDTA, 10 μg/ml leupeptin, and
1 mM Na3VO4). Lysates were cleared by centrifugation
at 14,000xg at 4°C. Protein content was quantified by the
BioRad Dc Protein Assay (Hertfordshire, UK). Following
the addition of 2X SDS-sample buffer and boiling, sam-
ples were loaded onto 7.5-10% SDS-PAGE gels and
transferred to PVDF (Fisher Scientific UK, Leicestershire,
UK). Membranes were blocked with either 5% non-fat
dry milk or 3% BSA, probed with the indicated anti-
bodies, and visualized following the addition of HRP
conjugated secondary antibodies (Dako UK Ltd., Cam-
bridgeshire, UK) and incubation with enhanced chemilu-
minescence (GE Healthcare UK Ltd., Buckinghamshire,
UK). Western blots were either directly reprobed or par-
allel Western blots were performed on the same cell
lysates for alpha-tubulin loading controls.
Cell surface biotinylation
Cells were washed in cold PBS, incubated 30 minutes
with 0.2 mg/ml EZ-Link Sulfo-NHS-Biotin (Fisher Scien-
tific UK Limited, Loughborough, UK) on ice. After
30 minutes, cells were washed two times in cold PBS
and lysed in immunoprecipitation buffer (200 mM NaCl,
75 mM Tris pH7.4, 7.5 mM EDTA, 7.5 mM EGTA, 1.5%
Triton-X 100 and 0.7% NP-40 with protease inhibitor
cocktail). Lysate was cleared at 14,000 xg for 10 minutes
at 4°C and the resulting supernatant was incubated with
anti-β3 integrin/CD61 antibody (clone VI-PL2; BD Bios-
ciences) overnight at 4°C, followed by addition of 15 μL
of 50 mg/ml Protein A-sepharose and incubation at 4°C
for 1 hour. Beads were washed four times in lysis buffer,
followed by addition of 2X SSB, and samples were rununder non-reducing conditions on 7.5% SDS-PAGE.
Western blot analysis was performed with HRP-conjugated
streptavidin (Fisher Scientific UK Limited).
Recombinant protein production
The pET27 TGFBI plasmid utilized for recombinant pro-
tein production in bacteria was a kind gift from Dr.
Ching Yuan (University of Minnesota, Minnesota, USA).
Both recombinant TGFBI and periostin were engineered
with a carboxy-terminal His-tag. Periostin cDNA was a
kind gift from Dr. Nick Lemoine (Barts, London, UK).
Periostin cDNA, lacking the amino-terminal signal pep-
tide, was cloned into the pET27 vector for subsequent
production of bacterial expressed recombinant protein.
Deletion constructs were made by PCR addition of NheI
and NdeI unique restriction sites for subsequent cloning
into the pET27 vector. Site-directed mutagenesis was
performed on pET27 TGFBI to produce an amino acid
RGD to RAE substitution using the oligonucleotide pri-
mer 5’-agacctcaggaaagagcggaggaacttgcagactctg-3’ and an
amino acid YH to SR substitution using the oligonucleo-
tide primer 5’-gaacttgccaacatcctgaaagccgccattggtgat-
gaaatcctgg-3’. All constructs were verified by sequencing.
All recombinant proteins were produced in Rosetta BL21
(DE3) E.coli (Merck, Nottingham, UK) and either puri-
fied from an insoluble fraction [34] for full-length TGFBI
and periostin or from a soluble fraction [35] utilizing Ni-
NTA agarose beads (Merck). Refolding of purified full-
length TGFBI and periostin was performed by buffer ex-
change through a PD10 Desalting Column (GE Health-
care, Buckinghamshire, UK) into 10 mM Tris–HCl pH
7.4, 0.5 M Arginine-HCl, and 10% Glycerol solution.
Adhesion assay
96-well or 24-well tissue culture treated plastic dishes
were incubated overnight at 37°C with 20 μg/ml of re-
combinant protein diluted in PBS. Dishes were subse-
quently washed with PBS, blocked with 3% BSA for
1 hour at 37°C, followed by washing with PBS and SF
media containing 0.1% BSA. Cells were collected, washed
once with growth media, washed twice with serum-free
media containing 0.1% BSA, and incubated in serum-free
media containing 0.1% BSA for 1 hour at 37°C in sus-
pension. Cells were plated on uncoated, poly-L-lysine, or
matrix-coated dishes for indicated time periods. Adher-
ent cells were subsequently washed once with PBS, fixed
in methanol, and stained with Giemsa (Fisher Scientific
UK). Stain was eluted with 10% acetic acid and an ab-
sorbance reading was obtained at 540 nm. To account
for non-specific adhesion, values from uncoated wells
were subtracted from all experimental values. All experi-
ments were performed in triplicate. Due to technical
variability of raw values between replicate experiments,
data were represented as percent adhesion to control. All
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ther one- or two-way Anova along with Bonferroni’s
multiple comparison test when appropriate. Error bars
represent standard deviation. Bright-field images were
taken with a DS-Fi1 CCD camera and processed with
Adobe PhotoshopW CS2.
Apoptosis and viability assays
For apoptosis analysis, cells plated on uncoated tissue
culture dishes were treated with varied concentrations of
Paclitaxel or DMSO vehicle control diluted in complete
growth media. Following incubation at 37°C for 24 hours,
both adherent and floating cells were harvested and
washed in cold PBS. The TACS Annexin-V Apoptosis kit
(R&D systems Europe Ltd.) was performed according to
manufacturer’s instructions. 10,000 cell events were
recorded on a BD FACS Calibur and data was analyzed
with FlowJo 8.8.4 flow cytometry analysis software (Tree
Star Inc., Ashland, Oregon, USA). Results are repre-
sented as the percentage of early apoptotic events
(Annexin-V positive, propidium iodide negative) com-
pared to total events and error bars represent standard
deviation. For cell viability analysis, cells were transiently
transfected with siRNA prior to replating on white 96-
well tissue culture dishes. Cells were treated with vehicle
(DMSO) or increasing concentrations of Paclitaxel for
48 hours prior to administration of the Cell Titre GloW
Luminescent cell viability reagent as per manufacturer’s
instructions (Promega UK, Southampton, UK). Results
were normalized to a DMSO treated control and the ex-
periment was performed in triplicate. Error bars repre-
sent standard deviation and a one-way anova along with
a Bonferroni multiple comparison test was performed.
Immunofluorescence microscopy
Cells were fixed in 3.7% Formaldehyde in PBS for 8 min-
utes and permeabilized with 0.2% Triton X-100 for
2 minutes. Fixed cells were incubated with primary anti-
body in TBS containing 1% BSA at 37°C for 1.5 hours,
washed in TBS, incubated with either Alexa FluorW 488
or 568 secondary antibodies (Invitrogen) in TBS contain-
ing 1% BSA, washed in TBS, and mounted in Fluorsave
(Calbiochem). For live cell immunostaining with anti-
αvβ3 integrin antibody (clone LM609), cells were first
washed into CO2-independent medium supplemented
with 2% FBS, next incubated in primary antibody for
20 minutes, followed by incubation with Alexa Fluor 488
antibody for 20 minutes. Cells were washed in PBS and
fixed for 2 minutes in ice-cold methanol. Nuclei were
stained with Hoechst and coverslips were mounted in
Fluorsave. Images were captured on a Leica Tandem SP5
confocal microscope (Leica-Microsystems, Milton Key-
nes, UK) or a Zeiss Axioplan epifluorescence microscope
equipped with a Hamamatsu ORCA-R2 CCD cameradriven by Simple PCI software (Carl Zeiss MicroImaging
Inc.) and processed with Adobe PhotoshopW CS2. Image
analysis of cell surface integrin immunostaining was per-
formed using ImageJ software. Briefly, the integrated in-
tensity of integrin immunostaining was calculated and
due to technical variability between replicate experi-
ments, values were normalized to control and repre-
sented as the percent change in fluorescence intensity.
The data represents at least 100 individual cells taken
from two independent experiments.
Bright-field time lapse video microscopy was per-
formed using a Nikon TE2000 PFS microscope equipped
with a DS-Fi1 CCD camera. Cells were plated on a
matrix-coated ibidi 35 mm μ-dish, low (Thistle Scientific,
Glasgow, UK) and images were acquired using a 10X ob-
jective every 2 minutes for 6 hours using NIS elements
software (Nikon Instruments Europe) in a temperature
controlled and 5% CO2 maintained environment.Results
Recombinant TGFBI and periostin support adhesion of
ovarian cancer cells and stimulate Akt phosphorylation
Both TGFBI and periostin contain conserved motifs
shown to mediate binding to the integrin receptor family.
However, although TGFBI and periostin retain the four
conserved fasciclin I domains, periostin contains a longer
carboxy-terminus lacking an RGD motif, which is
present in TGFBI (Figure 1A). Importantly, the RGD
motif has been implicated in integrin receptor binding
and has been shown to be necessary for cell adhesion to
various extracellular proteins, including fibronectin [36].
We first compared the functions of TGFBI and perios-
tin on ovarian cancer cells. Firstly, recombinant TGFBI
(rTGFBI) and periostin (rPOSTN) were produced from
bacteria and expression was verified by SDS-PAGE and
Western blot (Figure 1B). To validate the functions of
the recombinant proteins and to determine whether
ovarian cancer cells have differential binding to both
matrices, the SKOV3 ovarian cancer cell line was used in
adhesion assays. SKOV3 cells were capable of adhering
and spreading on both recombinant TGFBI and perios-
tin, although adhesion to periostin was less than TGFBI
or fibronectin (Figure 1C, 1D; Additional file 1: Movie
S1 and Additional file 2: Movie S2).
Previous reports have suggested periostin and TGFBI
are capable of stimulating Akt phosphorylation [27,28,37].
We evaluated the potential biochemical differences in Akt
phosphorylation following interaction of cells with either
rTGFBI or rPOSTN. As SKOV3 and other ovarian cancer
cell lines have constitutive activation of Akt we used NIH
3T3 cells, which are capable of supporting adhesion to
both rTGFBI and rPOSTN (Figure 1E), and have low basal
levels of Akt phosphorylation. Both rTGFBI and rPOSTN
Figure 1 Recombinant TGFBI and periostin support adhesion of ovarian cancer cells and stimulate Akt phosphorylation. A, Schematic
representation of the domain structure of TGFBI and periostin. Both TGFBI and periostin contain conserved Fasciclin I and EMI domains, while only
TGFBI contains an RGD motif. B, Purified bacterially expressed recombinant TGFBI (rTGFBI) and recombinant Periostin (rPOSTN). Coomassie brilliant
blue stained SDS-PAGE of purified rTGFBI and rPOSTN and Western blot (IB) probed with specific antibodies against TGFBI and periostin. C, Bright-
field images of SKOV3 adhesion to uncoated, fibronectin, rTGFBI, or rPOSTN coated tissue culture plastic. D, Results of three independent
adhesion experiments were normalized to poly-L-lysine and are represented as percent of fibronectin control, *p< 0.05, **p< 0.01. E, NIH3T3 cells
were replated on tissue culture wells coated with 10 μg/ml of fibronectin, rTGFBI, or rPeriostin and allowed to adhere for 30 minutes. Results of
two independent experiments were normalized to poly-L-lysine and represented as percent of fibronectin control. F, Western blot analysis of
NIH3T3 cell lysates following stimulation with 10 μg/ml of rTGFBI or rPeriostin in serum-free media for indicated time points. The membrane was
probed with antibodies specific to the phosphorylated Serine 473 amino acid residue of Akt and pan-Akt antibodies were utilized as loading control.
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3T3 cells (Figure 1F).
Integrin subunit expression influences the extent of TGFBI
adhesion
Primary ovarian tumor samples and ovarian cancer cell
lines have been shown to have variable expression of dif-
ferent integrin subunits [38]. This variable integrin ex-
pression profile may influence cell interactions with the
ECM. We characterized a panel of six ovarian cancer cell
lines for β1 and β3 integrin subunit expression. Western
blot analysis indicated ubiquitous expression of β1 integ-
rin while β3 integrin expression was limited to the
TR175, SKOV3 and the in vitro derived taxol-resistantSKOV3 TR cell lines (Figure 2A; Additional file 3: Figure
S1). SKOV3 cells (β1 and β3 integrin positive) preferen-
tially bound to recombinant TGFBI, while PEO1 cells
(β1 integrin positive, β3 integrin negative) preferentially
bound to recombinant periostin (Figure 2B). To further
evaluate the specificity of TGFBI and periostin for β1
and β3 integrin heterodimers we used function blocking
integrin antibodies and adhesion assays with SKOV3
cells. TGFBI predominantly signalled through an αvβ3
integrin-mediated mechanism, periostin and fibronectin
preferentially signalled through a β1 integrin-mediated
mechanism, and vitronectin primarily utilized αvβ3 and
αvβ5 integrins (Figure 2C). To ensure that the effect on
TGFBI was β3 integrin specific, we used the β3 integrin
Figure 2 Integrin subunit expression influences the extent of TGFBI adhesion. A, Western blot analysis of RIPA soluble lysates from a panel
of ovarian cancer cell lines probed with antibodies against the indicated proteins. SKOV3 TR cells are an in vitro-derived taxol resistant derivative
of the SKOV3 parental line. B, Relative adhesion of SKOV3 and PEO1 ovarian cancer cell lines to rTGFBI and rPeriostin. Results of two independent
experiments are represented as absorbance at 540 nm, **p< 0.01. C, SKOV3 cell adhesion to fibronectin, rTGFBI, rPOSTN, and vitronectin coated
tissue culture plastic in the presence of vehicle or the indicated integrin blocking antibodies. Results of at least three independent experiments
were normalized to poly-L-lysine and represented as percent of vehicle treated control.
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adhesion to rTGFBI following preincubation with an
αvβ3 integrin function blocking antibody (Additional file
4: Figure S2).
Loss of β1 integrin expression stimulates cell adhesion
and spreading to rTGFBI in ovarian cancer cells
The interaction of TGFBI with cell surface integrin
receptors is complex, and is likely cell-type specific [6].
Variable expression of different integrin subunits in ovar-
ian cancer has been reported, including upregulation of
β3 integrin expression and its association with metastasis[39,40]. Thus, we evaluated the effects of dynamic modu-
lation of the β1 and β3 integrin subunits during adhesion
to fibronectin, TGFBI, and periostin. To assess the speci-
ficity of the TGFBI interaction with specific cell surface
integrin heterodimers, short hairpin RNAs (shRNA) tar-
geting either β1 or β3 integrin were utilized to delineate
their individual contributions. SKOV3 cells were infected
with different Lentiviruses expressing two separate
shRNA targets to β1 integrin or β3 integrin as well as a
non-target control shRNA, and stable pools of cells were
selected with puromycin. All shRNA targets to β1 and
β3 integrin suppressed protein expression as assessed by
Figure 3 Loss of β1 integrin expression stimulates cell adhesion and spreading to rTGFBI in ovarian cancer cells. A, SKOV3 cells infected
with Lentivirus expressing shRNA against β1 integrin. Western blot analysis of RIPA soluble lysates utilizing antibodies against β1 integrin or alpha-
tubulin. Bright-field (a,c) and confocal immunofluorescence microscopy (b,d) images of control non-target shRNA (a,b) or β1 integrin shRNA (c,d)
treated cells following adhesion to rTGFBI. Rhodamine-phalloidin was utilized to visualize the actin cytoskeleton. Scale bar = 40 μm (confocal),
scale bar = 50 μm (bright-field). B, SKOV3 cells were either control non-target shRNA or β1 integrin shRNA treated followed by incubation on
either fibronectin, rTGFBI, or rPeriostin coated tissue culture plastic for 30 minutes. Results of three independent experiments were normalized to
poly-L-lysine and represented as percent of non-target control shRNA on each matrix protein. Significance of *p< 0.05 and **p< 0.01 is
compared to control shRNA. C, SKOV3 cells infected with Lentivirus expressing shRNA against β3 integrin. Cells expressing either non-target
shRNA or β3 integrin shRNA were replated on fibronectin, rTGFBI, or rPOSTN coated wells and allowed to adhere for 30 minutes. Results of three
independent experiments were normalized to poly-L-lysine and represented as percent of non-target control shRNA on each matrix. Significance
of *p< 0.05 and ***p< 0.001 is compared to control shRNA. D, PEO1 cells expressing either non-target shRNA or β1 integrin shRNA were replated
on fibronectin, rTGFBI, or rPOSTN coated wells and allowed to adhere for 1 hour. Results of three independent experiments were normalized to
poly-L-lysine and represented as percent of non-target control shRNA on each matrix. Significance of *p< 0.05, **p< 0.01, and ***p< 0.001 is
compared to control shRNA. E, SKOV3 cells following siRNA transfection against β1 integrin or non-target control were processed for live cell
immunostaining against the αvβ3 integrin heterodimer using the LM609 antibody (green). Hoechst stain was utilized to visualize the nuclei (blue).
Scale bar 40 μm. Quantitation of live cell immunostained avβ3 integrin heterodimers was achieved using ImageJ software. All experiments were
performed in duplicate and analysis was performed on greater than 100 cells/experiment. Results are represented as αvβ3 integrin cell surface
fluorescence intensity compared to control siRNA cells.
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expression, using two distinct shRNA target sequences
in SKOV3 cells, stimulated their adhesion and spreading
on recombinant TGFBI, while having a minimal effect
on recombinant periostin (Figure 3A, 3B). In contrast,
loss of β3 integrin expression specifically suppressed ad-
hesion to recombinant TGFBI (Figure 3C). Furthermore,
in the PEO1 cell line, which lacks β3 integrin expression
(Figure 2A; Additional file 3: Figure S1), reduced adhe-
sion to rTGFBI was observed following suppression of
β1 integrin expression, suggesting β3 integrin expression
is necessary for the increased adhesion associated with
SKOV3 cells (Figure 3D). This was confirmed by a re-
duction in adhesion of the β1 integrin shRNA expressing
SKOV3 cells to rTGFBI after incubation with an αvβ3
integrin-blocking antibody (Additional file 5: Figure S3).
Since suppression of β1 integrin expression had no ef-
fect on β3 integrin expression (data not shown), we nextFigure 4 Suppression of Syndecan-1 expression synergizes with the s
adhesion to rTGFBI. A, SKOV3 cells with stable expression of control non-
siRNA or Syndecan-1 siRNA. Flow cytometric analysis of β1 integrin and Sy
replated on either fibronectin, rTGFBI, or rPOSTN coated tissue culture well
poly-L-lysine and represented as percent of non-target control shRNA, *p<
immunoprecipitation of β3 integrin from SKOV3 cells expressing either non-
blot analysis was performed against β3 integrin or against biotin using HRP-
indicates β3 integrin subunit. D, SKOV3 cells with stable expression of contro
non-target siRNA or Syndecan-4 siRNA. Western blot analysis was performed
antibodies specific to the indicated proteins. Cells were replated on either f
to adhere for 30 minutes. Results were normalized to poly-L-lysine and repr
**p< 0.01 and ***p< 0.001 is compared to control shRNA.wanted to determine whether there was a modulation in
cell surface expression of β3 integrin. Following transfec-
tion of SKOV3 cells with β1 integrin siRNA, live cell
immunostaining revealed increased cell surface expres-
sion of the αvβ3 integrin heterodimer in β1 integrin
siRNA treated compared to control non-target siRNA
treated cells (Figure 3E). This cortically arranged immu-
nostaining pattern was verified when evaluating focal
adhesions, highlighted by paxillin, following fixation and
permeabilization of β1 integrin siRNA treated cells
(Additional file 6: Figure S4). These results were further
confirmed by cell surface biotinylation experiments
which illustrated increased cell surface biotinylation of
αvβ3 in β1 integrin siRNA treated cells (Figure 4C).
Thus, the increased adhesion to TGFBI associated with
suppression of β1 integrin expression is likely due to
modulation in β3 integrin expression on the cell surface.
Therefore, differences in response of ovarian cancer cellsuppression of β1 integrin expression to stimulate SKOV3
target or β1 integrin shRNA were transfected with control non-target
ndecan-1 cell surface protein expression was performed. B, Cells were
s and allowed to adhere for 30 minutes. Results were normalized to
0.05, ***p< 0.001. C, Cell surface biotinylation and
target control, β1 integrin, SDC-1, or β1 integrin/SDC-1 siRNA. Western
streptavidin. Arrow indicates αv integrin subunit and arrowhead
l non-target or β1 integrin shRNA were transfected with control
on RIPA soluble lysates and the membrane was probed with
ibronectin, rTGFBI, or rPOSTN coated tissue culture wells and allowed
esented as percent of non-target control shRNA. Significance of
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their β1/β3 integrin expression status.
Suppression of Syndecan-1 expression synergizes with the
suppression of β1 integrin expression to stimulate SKOV3
adhesion to rTGFBI
In addition to the integrin-family of receptors, other co-
receptors are required for extracellular matrix adhesion
and integrin activation [41]. One such group is the synde-
can family of cell surface receptors, which have a primary
role in synergizing with integrins to promote ECM binding
[42]. We next determined if the most relevant syndecan
members, Syndecan-1 and −4, could modulate adhesion to
rTGFBI and whether they influenced the integrin cross-
talk that occurs after alteration of integrin expression.
SKOV3 cells stably expressing either non-target control
shRNA or β1 integrin shRNA were transfected with
siRNA SMARTpool targeted against Syndecan-1. Flow
cytometric analysis was performed to verify suppression
of β1 integrin in addition to suppression of Syndecan-1Figure 5 Unlike periostin, the carboxy-terminus of rTGFBI supports adh
motif. A, Coomassie brilliant blue stained SDS-PAGE of full-length and vario
cells replated on tissue culture wells either uncoated or coated with poly-L
field images (a-f) were processed following Giemsa staining. rTGFBI compri
aa 497–683, and central domain comprises aa 24–506. Scale bar = 400 μm. C
to poly-L-lysine and represented as percent of fibronectin control. Significa
C-terminus RGDmut to full-length TGFBI. D, Coomassie stained SDS-PAGE o
with C-terminus of TGFBI. E, SKOV3 cells were replated on tissue culture we
30 minutes. Results are of three independent experiments, normalized to p
*p< 0.05, ***p< 0.001.protein expression (Figure 4A). Loss of both β1 integrin
and Syndecan-1 expression were synergistic in increas-
ing adhesion of SKOV3 cells to recombinant TGFBI. By
contrast, loss of Syndecan-1 expression alone had a
negative effect on adhesion to recombinant periostin
(Figure 4B). Furthermore, cell surface biotinylation
experiments revealed increased cell surface localization
of αvβ3 integrin in β1 integrin and SDC-1 single and
double knockdown treated cells (Figure 4C). Suppres-
sion of Syndecan-4 expression alone in these cells had
little effect and did not synergize with the loss of β1 in-
tegrin expression to stimulate adhesion to recombinant
TGFBI (Figure 4D). However, we did observe a signifi-
cant suppression of adhesion to periostin after knock-
down of Syndecan-4 expression (Figure 4D). Therefore,
Syndecan-1 and −4 expression is dispensable for adhe-
sion of ovarian cancer cells to rTGFBI, however, the
loss of Syndecan-1 expression can synergize with the
loss of β1 integrin expression to stimulate rTGFBI
adhesion.esion of ovarian cancer cells and is dependent on an intact RGD
us truncated constructs of rTGFBI purified from bacteria. B, SKOV3
-lysine, fibronectin and various rTGFBI constructs for 30 minutes. Bright-
ses aa 1–683, fourth FasI comprises aa 497–637, C-terminus comprises
, Adhesion results of three independent experiments were normalized
nce of ***p< 0.001 when comparing fourth FasI, central domain, and
f purified recombinant full-length and C-terminus of periostin along
lls coated with indicated constructs and allowed to adhere for
oly-L-lysine, and represented as percent of fibronectin control,
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adhesion of ovarian cancer cells and is dependent on an
intact RGD motif
The specificity of TGFBI for distinct integrin heterodi-
mers may be dictated by different protein binding motifs
as compared to those within periostin [6]. Recombinant
truncated TGFBI constructs were produced and purified
from bacteria to test which motifs were required for ad-
hesion of SKOV3 cells (Figure 5A). The carboxy-
terminus of TGFBI (aa 498–683), which contains the
fourth fasciclin I domain and the RGD motif, was cap-
able of supporting SKOV3 cell adhesion similar to full-
length rTGFBI. However, the fourth fasciclin I domain
alone (aa 498–637), previously shown to support
HUVEC and human fibroblast cell adhesion [15,43], and
the central domain (aa 24–506) were unable to support
SKOV3 adhesion (Figure 5B, 5C). Furthermore, muta-
genesis of the RGD motif to amino acid residues RAE in
the carboxy-terminal truncated form of TGFBI (aa 498–
683) abrogated adhesion of SKOV3 cells (Figure 5B, 5C).
As the carboxy-terminus of periostin includes the
fourth fasciclin domain, but not a RGD motif, we asked
if this region was sufficient for adhesion. Therefore,
SKOV3 cells were subjected to an adhesion assay on bac-
terially expressed recombinant TGFBI and periostin that
each comprise the fourth fasciclin I domain through to
the end of the protein sequence (Figure 5D). TheFigure 6 The RGD motif of TGFBI is necessary, but not sufficient, for a
Coomassie stained SDS-PAGE of purified wild-type, RGDmut, or YHmut of full
replated on tissue culture wells coated with indicated constructs and allowed
were normalized to poly-L-lysine and represented as percent of fibronectin co
SKOV3 cells pre-incubated with either the fibronectin RGD peptide (GRGDSP)
coated with fibronectin or rTGFBI. Results of two independent experiments ar
*p< 0.05 is compared to no peptide control. C, Adhesion assays were perform
rTGFBI, or rTGFBI RGDmut. Results of two independent experiments were nor
absorbance at 540 nm.carboxy-terminus of periostin was unable to support cell
adhesion in contrast to TGFBI (Figure 5E).
The RGD motif of TGFBI is necessary, but not sufficient,
for adhesion of ovarian cancer cells expressing β3
integrin
To further understand how the fourth fasciclin I domain
and the RGD motif cooperate with other TGFBI
domains, we evaluated whether mutation of the RGD
motif to amino acid residues RAE would affect the ability
of full-length TGFBI to support SKOV3 adhesion. In
these experiments we found that the RGD to RAE muta-
tion in full-length TGFBI significantly reduced SKOV3
adhesion (Figure 6A). While mutation of the YH motif in
the fourth Fasciclin I domain, previously shown to be ne-
cessary for avβ3 integrin-mediated adhesion of HUVEC
cells [15], did not affect cell adhesion (Figure 6A).
Short RGD peptides derived from fibronectin have
been previously reported to function as inhibitors of
fibronectin adhesion and migration [44,45]. Therefore,
we tested whether the ERGDEL peptide derived from
TGFBI was capable of competitively inhibiting adhesion
of ovarian cancer cells to fibronectin and rTGFBI.
Pretreatment of cells with the classical fibronectin
GRGDSP peptide was capable of inhibiting adhesion to
both fibronectin and rTGFBI (Figure 6B). By contrast,
pretreatment with the TGFBI ERGDEL peptide did notdhesion of ovarian cancer cells expressing β3 integrin. A,
-length recombinant TGFBI protein from bacteria. SKOV3 cells were
to adhere for 30 minutes. Results of three independent experiments
ntrol. Significance of ***p< 0.001 is compared to full-length rTGFBI. B,
or the TGFBI RGD peptide (ERGDEL) were replated on tissue culture wells
e represented as percent of control without peptide. Significance of
ed with SKOV3 and PEO1 cells plated on poly-D-lysine, fibronectin,
malized to adhesion on poly-D-lysine and are represented as relative
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Therefore, the RGD motif of TGFBI is necessary, but is
not sufficient, to support adhesion of SKOV3 cells and
binding either requires a greater number of flanking
amino acids or a complex with the fourth Fasciclin I
domain.
This may be further modulated by the integrin expres-
sion profile that dictates the mechanism by which TGFBIFigure 7 Suppression of different integrin and ECM components has d
A, Western blot analysis was performed on SKOV3 cells transfected with ei
Cells were subjected to varying concentrations of paclitaxel for 24 hours fo
staining, *p< 0.05, **p< 0.01. B, Cell titre glo cell viability assay performed
cells, treated with increasing concentrations of Paclitaxel for 48 hours. **p<
expressing either non-target control shRNA, TGFBI shRNA, or two separate
RIPA soluble lysates using antibodies to the specified proteins. Cells were t
propidium iodide staining, and subsequently analyzed by flow cytometry. E
increase in cells in early apoptosis, **p< 0.01.interacts with the cell surface, as PEO1 cells, which lack
β3 integrin, do not require the RGD motif of TGFBI for
adhesion (Figure 6C). This is in contrast to the SKOV3
cell line, which requires the RGD motif of TGFBI for
maximal adhesion (Figure 6A, 6C). Therefore, although
ovarian cancer cells have the ability to adhere to both
periostin and TGFBI, they likely utilize distinct
mechanisms.istinct effects on paclitaxel-induced death in ovarian cancer cells.
ther non-target control siRNA, β1 integrin siRNA, or β3 integrin siRNA.
llowed by flow cytometric analysis of Annexin-V and propidium iodide
on non-target control, β1 integrin, or β3 integrin siRNA expressing
0.01, ***p< 0.001. C, SKOV3 cells were infected with Lentivirus
fibronectin shRNA targets. Western blot analysis was performed on
reated with 0.3 μM paclitaxel for 24 hours followed by Annexin-V and
xperiments were performed in triplicate and are represented as fold
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has distinct effects on paclitaxel-induced death in ovarian
cancer cells
Integrin-mediated signaling has been suggested to influ-
ence the cytotoxic effects of paclitaxel on cancer cells
[1,30,46]. We have previously shown that loss of TGFBI
expression subsequently leads to cells becoming resistant
to paclitaxel-induced cell death, dependent on β3 integ-
rin function [1]. Studies in breast cancer cells indicated
that fibronectin-mediated and β1 integrin-dependent sig-
naling was required for a paclitaxel resistant phenotype.
Therefore, we directly tested whether there was specifi-
city among different integrin heterodimers that dictated
the response of cells to paclitaxel. We used siRNA to
suppress β1 and β3 integrin expression in SKOV3 cells,
and evaluated response to paclitaxel-induced death. Im-
portantly, compared to control, loss of β3 integrin ex-
pression induced a partial paclitaxel-resistant phenotype,
as shown by a decrease in apoptosis and an increase in
cell viability, while the loss of β1 integrin expression had
no effect on apoptosis and a partial decrease in cell via-
bility, suggesting a minor paclitaxel-sensitive phenotype,
consistent with previous reports [30] (Figure 7A, 7B).
Therefore, our data suggest that discrete signaling path-
ways may exist downstream of β1 and β3 integrin acti-
vation that influence the response of cells to paclitaxel
induced death, which may provide a unique role for β3
integrin-specific ECM proteins, such as TGFBI, in this
process. This is further supported by the loss of TGFBI
expression leading to a paclitaxel resistant phenotype,
while suppression of fibronectin expression, preferen-
tially signaling through β1-integrin, inducing a paclitaxel
sensitive phenotype (Figure 7C). Therefore, deregulation
of distinct integrin-mediated signaling pathways may
have contrasting effects on paclitaxel response.
Discussion
TGFBI is a multifunctional protein implicated in a variety
of physiological processes including cell growth, wound
healing, inflammation, and developmental morphogenesis
[6]. However, its dysregulation can lead to the pathogen-
esis of a variety of diseases, including cancer [6]. More
specifically, recent evidence suggests that TGFBI is
dysregulated in ovarian cancer and its expression level
may influence cancer response to the chemotherapeutic
agent paclitaxel [1]. In addition, extracellular TGFBI
increases the motility and invasiveness of ovarian cancer
cells and stimulates a peritoneal cell interaction [47].
Therefore, we sought to understand the molecular
mechanisms that influence TGFBI function and its inter-
relationship with other ECM components known to be
present in the tumor microenvironment in order to better
determine potential therapeutic targets and indicators of
treatment response.In ovarian cancer cells, which express both the β1 and
β3 integrin subunits, TGFBI preferentially interacts with
cells through an αvβ3 integrin-mediated mechanism.
This is in contrast to the predominant β1 integrin-
mediated mechanism elicited by fibronectin and perios-
tin (Figure 2C). Although this contradicts recent evi-
dence that suggests periostin primarily interacts with
ovarian cancer cells via an αvβ3 integrin-dependent
mechanism [24], it also suggests a delicate balance may
exist between different integrin receptors on the cell sur-
face that dictate specificity to the ECM. This is further
supported by our data showing that loss of β1 integrin in
SKOV3 cells increases adhesion to rTGFBI, but not to
fibronectin or periostin, in an αvβ3 integrin dependent
manner (Figure 3; Additional file 5: Figure S3).
Additionally, integrin cross-talk may play a major role
in the diversity seen within different cell systems and
within different tumor types that have varying integrin
subunit expression profiles. For example, divergent sig-
naling through β1 and β3 integrins has major impacts
on downstream Rho GTPase signaling, which may subse-
quently result in contrasting effects on cell adhesion and
migration [48]. In addition, distinct β1 and β3 integrin
expression along with oncogene expression, such as
oncogenic Src, may differentially influence chemosensi-
tivity [49]. Our data supports this notion as suppression
of β1 integrin expression stimulates a TGFBI-β3 integ-
rin-mediated adhesion response (Figure 3). Although our
data suggests an increased cell surface expression of the
αvβ3 integrin heterodimer following suppression of β1
integrin expression (Figure 3E, 4C), there likely also
exists cross-talk between downstream signaling com-
plexes associated with the activation of different integrin
receptors. Furthermore, our data indicate that in ovarian
cancer cells the loss of β3 integrin expression partially
induces a paclitaxel-resistant phenotype, while loss of β1
integrin expression leads to a potential paclitaxel-sensitive
phenotype. With regards to integrin receptor cross-
talk, it has been previously reported that forced expres-
sion of α5β1 integrin negatively regulates αvβ3 integrin
function in Chinese hamster ovary cells [31]. In addition,
it has been shown, with regards to the α3 noncollagen-
ous domain of collagen IV, that the α3β1 heterodimer
can modulate αvβ3-mediated cell adhesion [32]. Lastly,
β1 integrin activation negatively effects αvβ3 activation
via activation of PKA and inhibition of PP1 activity [33].
Since β3 integrin expression has been suggested to be a
potential prognostic biomarker in ovarian cancer [50], it
will be important to delineate the specific β3 integrin-
dependent signals and determine their impact on ovarian
carcinogenesis and chemotherapy response.
Attachment of ovarian cancer to the mesothelium and
its associated ECM, which lines the peritoneal cavity,
may not be exclusively integrin-mediated [38,51].
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tors may be involved in mediating adhesion in the tumor
microenvironment. The primary co-receptor family
involved in cell-ECM adhesion, which synergizes with
integrin engagement to mediate a complete cellular
response, is the Syndecan family of receptors [42].
For αvβ3 adhesion, Syndecan-1 is the predominant co-
receptor that mediates this process [52]. It is important to
note that although Syndecan-1 expression is absent in
the normal ovary, it is upregulated in ovarian cancer as
well as in tumor stroma [53]. Our data suggests that the
loss of Syndecan-1 cooperates with the loss of β1 integ-
rin to stimulate adhesion to TGFBI and is therefore dis-
pensable for TGFBI adhesion. Thus, for ovarian cancer
cells, it appears neither Syndecan-1 nor Syndecan-4 is
necessary for adhesion to TGFBI, nor does the loss of
Syndecan-4 synergize with αvβ3 to stimulate adhesion to
TGFBI. In contrast, for periostin, loss of both Syndecan-1
and Syndecan-4 negatively affects ovarian cancer cell
adhesion, which supports the notion that periostin uti-
lizes a distinct mode of cellular interaction.
Previous literature has attempted to dissect the specific
domains and motifs within TGFBI that are critical for its
interactions with the cell surface. Since these results
seem to be cell-type and system specific, we attempted
to extend a similar analysis with respect to ovarian can-
cer cells, including the comparison to its paralogue, peri-
ostin, which has been suggested to have a proactive role
in ovarian cancer migration [24]. Importantly, unlike
TGFBI, the periostin carboxy-terminus, which lacks an
RGD motif, is unable to support adhesion. This suggests
that the specificity of TGFBI and periostin for their
respective cell surface receptors is partially dictated by
differences in this region.
The function of the TGFBI-derived RGD appears to vary
depending on the cell-based system and the primary integ-
rin heterodimeric receptor. Initially, it was suggested that
the carboxy-terminus underwent proteolytic processing
resulting in loss of the RGD motif [54,55]. In addition, this
carboxy-terminal released peptide induced apoptosis in
CHO cells is dependent on an intact RGD motif [55].
However, in vitro biochemical analysis suggested the po-
tential carboxy-terminal cleavage site on human TGFBI
lies downstream of the RGD motif suggesting it is not
cleaved from the full-length protein [56]. Therefore, a ma-
ture TGFBI protein that contains the RGD motif is likely
functional in a biological context. This is supported by re-
cent data that suggests the RGD motif of TGFBI is neces-
sary for promoting extravasation of metastatic colon
cancer cells [16]. Our results suggest that the RGD motif
of full-length TGFBI is necessary, but not sufficient, for
ovarian cancer cell adhesion, thus indicating it may co-
operate with flanking residues or other motifs, potentially
present within the fourth Fasciclin I domain to mediatethis process. Importantly, we found that the TGFBI
derived RGD peptide (ERGDEL) was unable to competi-
tively inhibit SKOV3 adhesion to rTGFBI, suggesting its
use as a therapeutic agent to inhibit TGFBI function may
depend on the cellular context.
Conclusions
Ovarian cancer is a complex disease where the tumor
microenvironment plays an active role in the dissemin-
ation of the disease and influences the response to chemo-
therapy. Since it has previously been shown that
fibronectin-mediated β1 integrin signaling represses pacli-
taxel-induced cell death [30], specific ECM-receptor path-
ways may be important in differentially modulating
chemotherapeutic response. This is confirmed by our data
which showed suppression of fibronectin expression sensi-
tizes cells to paclitaxel-induced death, while suppression of
TGFBI leads to a resistant phenotype (Figure 7) [1]. This is
further supported by recent data in non-small cell lung
cancer showing that TGFBI-mediated induction of apop-
tosis in response to chemotherapy requires the αvβ3 integ-
rin receptor [57]. In addition, distinct ECM-integrin
receptor engagement may trigger intracellular cues that
stabilize the microtubule cytoskeleton, which has been
suggested to be a mechanism to enhance the cytotoxicity
of paclitaxel [58]. Therefore, it will be crucial in a clinical
context to define the relationship between discrete integrin
heterodimers and their respective extracellular binding
partners in order to understand the intracellular signaling
pathways that occur. Importantly, further characterization
of the differential signaling downstream of TGFBI-β3 in-
tegrin engagement in comparison to other ECM-receptor
mediated pathways will be needed to identify distinct
mechanisms of chemotherapeutic response.Additional files
Additional file 1: Movie S1. Bright-field time lapse video microscopy of
an SKOV3 cell plated on rTGFBI in serum-free media. Images were
acquired every 2 minutes for a period of 6 hours.
Additional file 2: Movie S2. Bright-field time lapse video microscopy of
an SKOV3 cell plated on fibronectin in serum-free media. Images were
acquired every 2 minutes for a period of 6 hours.
Additional file 3: Figure S1. Flow cytometric analysis of SKOV3, PEO1,
and TR125 cell surface integrin expression following immunostaining with
either IgG control or integrin-specific antibodies (P5D2 - β1, LM609 - αvβ3,
P1F6 - αvβ5).
Additional file 4: Figure S2. PEO1 cell adhesion to fibronectin, rTGFBI,
rPOSTN and vitronectin coated tissue culture plastic in the presence of
vehicle or the indicated integrin receptor blocking antibodies. Results are
represented as the mean of two independent experiments normalized to
uncoated and poly-L-lysine coated wells and represented as percent of
vehicle treated control. Error bars represent the standard deviation.
Additional file 5: Figure S3. SKOV3 cells expressing either control shRNA or
β1 shRNA were left untreated or pretreated with the αvβ3 blocking antibody,
LM609, prior to replating on rTGFBI. Relative adhesion was quantitated by
measuring the absorbance at 540 nm and values were normalized to an
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http://www.molecular-cancer.com/content/11/1/36uncoated well. Results represent 3 independent experiments and error
bars represent standard deviation. *p< 0.05, **p< 0.001.
Additional file 6: Figure S4. Immunofluorescence microscopy of
SKOV3 cells stably expressing control or β1 integrin shRNA. Fixed and
permeabilized cells were immunostained for paxillin, to highlight focal
adhesions, and the actin cytoskeleton was visualized with Alexa Flour
568-phallloidin. Scale bar 40 μm.
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